XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38
Research Article
The Journal of Clinical Endocrinology and Metabolism.

Thyroid Channel
subscribe to Thyroid newsletter

Latest Research : Cancer : Thyroid

   DISCUSS   |   EMAIL   |   PRINT
A novel molecular diagnostic tool to assess risk for patients with papillary thyroid cancer
Jan 7, 2006, 17:46, Reviewed by: Dr. Rashmi Yadav


“By illustrating a higher risk of poorer outcomes and recurrence, these results should help physicians perform better risk analysis of patients with PTC, which in turn will lead to more tailored treatment of the disease."


 
Scientists at Johns Hopkins have found that a mutation in the gene that triggers production of a tumor growth protein is linked to poorer outcomes for patients with papillary thyroid cancer (PTC). A report on the study is published in the December issue of The Journal of Clinical Endocrinology and Metabolism.

Mingzhao Xing, M.D., Ph.D., an assistant professor in the Division of Endocrinology and Metabolism at The Johns Hopkins University School of Medicine, led the multi-center study. “This discovery should help physicians rate risk levels for patients with PTC,” he says.

The gene, called BRAF, is part of a signaling pathway that, when activated, is known to cause tumor growth, and mutations in BRAF have been linked to a variety of human cancers, the researchers say.

For the study, Xing and colleagues looked at information from 219 PTC patients from 1990 to 2004. The relationship among BRAF mutations, initial tumor characteristics, cancer recurrence and clinical outcomes was analyzed.

Results showed a “significant association” between BRAF mutation and spread of the cancer from the thyroid, lymph node metastasis, and advanced tumor stage at the time of surgery to remove the cancerous thyroid gland. The thyroid, a gland located beneath the voice box (larynx) that produces thyroid hormone, helps regulate body cell growth and metabolism. Results also showed that, given an average follow-up of three to four years, 25 percent of patients with BRAF mutations experienced tumor recurrence compared to 9 percent without evidence of BRAF mutations.

BRAF mutation was also an independent predictor of recurrence in patients with early disease, with 22 percent recurrence in those who had BRAF mutations versus only 5 percent in patients without the mutation.

Finally, BRAF mutation was more frequently associated with treatment failure in recurrent disease, according to the study.

“By illustrating a higher risk of poorer outcomes and recurrence, these results should help physicians perform better risk analysis of patients with PTC, which in turn will lead to more tailored treatment of the disease,” Xing said.

PTC is the most common thyroid cancer, accounting for 80 percent or more of thyroid malignancies. Although PTC is usually curable with surgical removal of the gland, often followed by radioiodine treatment, many cases recur and are fatal.

The ability to predict outcome has traditionally been based on such factors as patient age and gender, tumor size and the nature of the spread of disease. However, these criteria often leave uncertainty regarding the risk of tumor progression and recurrence.

“What we have is a novel molecular diagnostic tool that will improve existing clinical efforts,” Xing said.
The study patients were recruited from The Johns Hopkins University School of Medicine; The Yale University School of Medicine; The Hospital for Endocrine Surgery in Kiev, Ukraine; and The University of Bologna Hospital in Bologna, Italy.

Other contributors from Hopkins include William H. Westra, M.D., professor in the Department of Pathology; Ralph P. Tufano, M.D, assistant professor in the Department of Otolaryngology -- Head and Neck Surgery; David Sidransky, M.D., professor in the Department of Otolaryngology -- Head and Neck Surgery, and Paul W. Ladenson, M.D., director of the Division of Endocrinology and Metabolism.

The study was supported by grants from the National Institutes of Health and the Flight Attendant Medical Research Institute.

 

- A report on the study is published in the December issue of The Journal of Clinical Endocrinology and Metabolism.
 

http://www.hopkinsmedicine.org/

 
Subscribe to Thyroid Newsletter
E-mail Address:

 

Johns Hopkins Medicine
Office of Corporate Communications
CONTACT: Eric Vohr
PHONE: 410-955-8665
E-MAIL:


Related Thyroid News

Study demonstrates link between thyroid cancer and the Chornobyl accident
Recombinant TSH therapy promises better quality of life for thyroid cancer patients
A novel molecular diagnostic tool to assess risk for patients with papillary thyroid cancer
Gene Activity can Differentiate Follicular Adenoma from Follicular Thyroid Cancer
Cincinnati study of Chernobyl residents uncovers new cause of thyroid cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us